Session » Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1355

ASAH1 Gene Mutations Cause Acid Ceramidase Deficiency (Farber Disease), with Symptoms Including Arthritis and Subcutaneous Nodules. Patients Are Often Misdiagnosed with JIA, and Slowly Progressive Disease May Only be Diagnosed in Adulthood

9:00AM-11:00AM: Abstract Number: 1350

Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience

9:00AM-11:00AM: Abstract Number: 1344

Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study

9:00AM-11:00AM: Abstract Number: 1349

Clinical Analysis of Hypertrophic Pachymeningitis

9:00AM-11:00AM: Abstract Number: 1357

Clinical Description of Patients with Cytoplasmic Discrete Speckles on Indirect Immunofluorescence on HEp-2 Cells in a Universitary Hospital

9:00AM-11:00AM: Abstract Number: 1330

Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear

9:00AM-11:00AM: Abstract Number: 1334

Contribution of Diagnostic Investigations in the Management of Uveitis: Retrospective Analysis of 300 Patients

9:00AM-11:00AM: Abstract Number: 1356

Correlation of Erythrocyte Sedimentation Rate with Glycohemoglobin Values and Other Patient Factors

9:00AM-11:00AM: Abstract Number: 1360

Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar

9:00AM-11:00AM: Abstract Number: 1331

Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience

9:00AM-11:00AM: Abstract Number: 1337

Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases

9:00AM-11:00AM: Abstract Number: 1329

Efficacy and Safety of Biologics in Relapsing Polychondritis: A National Multicenter Study in France

9:00AM-11:00AM: Abstract Number: 1343

Efficacy of Biological-Targeted Treatments in MDS-Related Systemic Autoimmune Diseases: Multicenter Retrospective Study of 28 Patients

9:00AM-11:00AM: Abstract Number: 1346

Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1335

Long–Term Safety and Efficacy of Adalimumab in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis in an Ongoing Open-Label Study

9:00AM-11:00AM: Abstract Number: 1351

Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 1348

Neuromyelitis Optica: Patient Characteristics and Treatment Patterns Among Rheumatologists Versus Non-Rheumatologists

9:00AM-11:00AM: Abstract Number: 1359

New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases

9:00AM-11:00AM: Abstract Number: 1352

Predictors of Mortality in Rheumatic Disease Patients with CMV Infection

9:00AM-11:00AM: Abstract Number: 1333

Relevance of Granulomatous Presentation for the Diagnosis and Outcome of Uveitis: Retrospective Case-Control Study of 251 Patients

9:00AM-11:00AM: Abstract Number: 1358

Response of Hidradenitis Suppurativa to Biologic Therapy

9:00AM-11:00AM: Abstract Number: 1341

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1339

Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity

9:00AM-11:00AM: Abstract Number: 1353

Risk Factors of Pulmonary Mycobacterium Avium-Comlex (MAC) Disease and the Significance of Anti-MAC Antibody in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1332

Severe Complications and Immunosuppressive Treatments in 33 Patients with Relapsing Polychondritis

9:00AM-11:00AM: Abstract Number: 1347

Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis: Characteristics, Treatment and Outcome in 251 Cases from the Literature

9:00AM-11:00AM: Abstract Number: 1336

Tocilizumab for Uveitic Cystoid Macular Edema Refractory to Other Synthetic and Biological Immunosuppressive Drugs. Multicenter Study of 25 Patients

9:00AM-11:00AM: Abstract Number: 1340

Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution

9:00AM-11:00AM: Abstract Number: 1354

Ultrasound Verified Inflammation and Structural Abnormalities in Patients with Hemochromatosis with and without Associated Arthropathy

9:00AM-11:00AM: Abstract Number: 1345

Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time

9:00AM-11:00AM: Abstract Number: 1342

Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports

9:00AM-11:00AM: Abstract Number: 1338

Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].